Fig. 2.
Baf-A1 treatment has no effect on influenza A virus (IAV) binding. A549 cells were treated with different concentrations of Baf-A1 for 24 h and then incubated with A/PR/8/34 virus at a MOI of 10 plaque-forming units (PFU)/cell. Cells were exposed to influenza virus on ice for 90 min to allow viral binding, then washed, fixed, and analyzed by immunofluorescence (IF) microscopy and FACS by using anti-vNP antibody. A: typical confocal images of A549 cells stained for IAV particles with a mouse anti-vNP monoclonal antibody. Initial attachment and binding of IAV was not affected by Baf-A1 treatment since both Baf-A1-treated (c, d, e, and f) and Baf-A1-untreated (b) A549 cells showed comparable high levels of virus binding. vNP, IAV nuclear protein. B: representative FACS histograms of Baf-A1 pretreated A549 cells infected with influenza virus, showing number of attached virus particles in Baf-A1-treated cells (in red) compared with nontreated cells (in black). C: quantified data of the FACS histograms displayed in B. Treatment of A549 cells with different concentrations of Baf-A1 did not affect the numbers of viruses attached to the cells. Error bars represent the standard deviation for 3 independent experiments. Ø, No Baf-A1 treatment; Nuc, nucleus; NS, not significant.